Erytech Pharma SA (ADR) (NASDAQ:ERYP): Julian Baker And Felix Baker’s Baker Bros. Advisors filed an amended 13D.
You can check out Baker Bros. Advisors’ latest holdings and filings here.
Please follow Baker Bros. Advisors (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Baker Bros. Advisors or update its stock holdings.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Baker Bros. Advisors||4,898,337||0||4,898,337||0||4,898,337||27.3%|
|Baker Bros. Advisors (GP)||4,898,337||0||4,898,337||0||4,898,337||27.3%|
|Julian C. Baker||4,898,337||0||4,898,337||0||4,898,337||27.3%|
|Felix J. Baker||4,898,337||0||4,898,337||0||4,898,337||27.3%|
Page 1 of 10 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
Under the Securities Exchange Act of
(Amendment No. )*
ERYTECH Pharma S.A.
(Name of Issuer)
Ordinary Shares, nominal value €0.10
(Title of Class of Securities)
Alexandra A. Toohey
Chief Financial Officer
Baker Bros. Advisors LP
860 Washington Street, 3rd Floor
New York, NY 10014
(Name, address and telephone number of person
authorized to receive notices and communications)
November 10, 2017
(Date of event which requires filing of
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨
(Continued on the following pages)
Note: Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to
* The remainder of this cover page shall be filled out for
a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).